Skip to main content

Table 3 Index OAC Dose

From: Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study

Year

Warfarin

Dabigatran

Rivaroxaban

Apixaban

Dose

2.5

75

110

150a

2.5

10

15

20a

2.5

5a

2010

6491 (100.00)

4 (44.44)

5 (55.56)

-

-

2 (100.00)

-

-

-

-

2011

7125 (100.00)

10 (9.62)

63 (60.58)

31 (29.81)

-

8 (100.00)

-

-

-

-

2012

7066 (100.00)

32 (6.40)

202 (40.40)

266 (53.20)

-

14 (24.14)

2 (3.45)

42 (72.41)

1 (100.00)

-

2013

3943 (100.00)

25 (1.00)

907 (36.25)

1570 (62.75)

-

46 (3.47)

353 (26.60)

928 (69.93)

55 (29.89)

129 (70.11)

2014

2633 (100.00)

11 (0.57)

565 (29.26)

1355 (70.17)

-

21 (1.37)

396 (25.75)

1121 (72.89)

453 (25.84)

1300 (74.16)

2015

1479 (100.00)

9 (1.24)

225 (31.08)

490 (67.68)

6 (0.31)

20 (1.02)

423 (21.63)

1507 (77.04)

868 (23.19)

2875 (76.81)

2016

801 (100.00)

5 (0.95)

171 (32.57)

349 (66.48)

4 (0.23)

10 (0.58)

284 (16.49)

1424 (82.69)

1101 (22.07)

3888 (77.93)

2017

416 (100.00)

1 (0.23)

154 (35.16)

283 (64.61)

1 (0.08)

13 (1.07)

219 (18.10)

977 (80.74)

1079 (18.70)

4690 (81.30)

2018

114 (100.00)

1 (0.61)

58 (35.58)

104 (63.80)

2 (0.54)

2 (0.54)

65 (17.57)

301 (81.35)

450 (18.94)

1926 (81.06)

  1. Note: dose in milligrams, astandard dose